Biodesix, Inc. (NASDAQ:BDSX) Insider Sells $15,408.16 in Stock

Biodesix, Inc. (NASDAQ:BDSX) insider Gary Anthony Pestano sold 16,748 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $15,408.16. Following the completion of the sale, the insider now owns 156,008 shares of the company’s stock, valued at approximately $143,527.36. This represents a 9.69 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Biodesix Price Performance

BDSX stock opened at $0.94 on Thursday. The stock has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.49. The stock has a market cap of $136.74 million, a PE ratio of -2.41 and a beta of 1.06. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a 1 year low of $0.86 and a 1 year high of $2.04.

Hedge Funds Weigh In On Biodesix

A number of large investors have recently added to or reduced their stakes in BDSX. Barclays PLC increased its holdings in Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares in the last quarter. HighTower Advisors LLC increased its holdings in Biodesix by 17.1% during the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after purchasing an additional 22,500 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in Biodesix during the 3rd quarter worth about $262,000. Stephens Inc. AR bought a new position in Biodesix during the 4th quarter worth about $303,000. Finally, Geode Capital Management LLC increased its holdings in Biodesix by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock worth $1,266,000 after purchasing an additional 22,623 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.